There are currently 105 active clinical trials seeking participants for Endometrial Cancer research studies. The states with the highest number of trials for Endometrial Cancer participants are Texas, New York, California and Ohio.
Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer
NCT04586959
Recruiting
This is a prospective, multi-center, randomized non-inferiority phase III study to evaluate if patients undergoing a minimally invasive surgery for early stage uterine cancer have cancer cells in the fluid that is obtained at the time of their surgery when a uterine manipulator is placed versus patients who do not have a uterine manipulator placed.
Gender:
FEMALE
Ages:
Between 18 years and 90 years
Trial Updated:
12/18/2024
Locations: Cleveland Clinic, Cleveland, Ohio +4 locations
Conditions: ENDOMETRIAL CANCER
Register for Updates
Adjuvant Hypofractionated Whole Pelvis Radiation Therapy in Endometrial Cancer
NCT04458402
Recruiting
Studying adjuvant hypofractionated whole pelvis radiation therapy in Endometrial Cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/27/2024
Locations: University of Cincinnati Medical Center, Cincinnati, Ohio
Conditions: Endometrial Cancer
Register for Updates
Quality of Life Assessment of Radiotherapy in Recurrent Head and Neck Cancer
NCT05850663
Recruiting
The purpose of this study is to examine the uses of a mobile health-based assessment and symptom monitoring platform.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Stephenson Cancer Center, Oklahoma City, Oklahoma
Conditions: Head and Neck Cancer, Gynecologic Cancer, Cervical Cancer, Endometrial Cancer
Register for Updates
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
NCT06257264
Recruiting
This study is a first-in-human (FIH), Phase 1a/1b study of BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-68501 in participants with advanced, nonresectable, or metastatic solid tumors as monotherapy and in combination with fulvestrant with or without BGB-43395, a selective CDK4 inhibitor, in adults with hormone receptor positive (HR+)/human epidermal growth factor rece... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2025
Locations: Hoag Memorial Presbyterian, Newport, California +30 locations
Conditions: Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced Solid Tumor, Endometrial Cancer, Prostate Cancer, TNBC - Triple-Negative Breast Cancer, GastroEsophageal Cancer, Bladder Cancer
Register for Updates
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
NCT06132958
Recruiting
Researchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with platinum based therapy (a type of chemotherapy) and immunotherapy. Immunotherapy is a treatment that helps the immune system fight cancer. This clinical study will compare MK-2870 sacituzumab tirumotecan to chemotherapy. The goal of the study is to learn if people who receive MK-2870 sacituzumab tirumotecan live longer overall and without the cancer getting worse compared... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/21/2025
Locations: USA Mitchell Cancer Institute ( Site 4142), Mobile, Alabama +234 locations
Conditions: Endometrial Cancer
Register for Updates
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
NCT06695845
Recruiting
The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: Arizona Oncology Associates, PC - NAHOA, Prescott, Arizona +13 locations
Conditions: Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer, Colorectal Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Urothelial Carcinoma, Salivary Gland Cancer, Pancreatic Cancer, HER-2 Protein Overexpression
Register for Updates
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
NCT06481592
Recruiting
The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated endometrial cancer.
Gender:
FEMALE
Ages:
Between 18 years and 70 years
Trial Updated:
03/17/2025
Locations: University of Southern California, Los Angeles, California +6 locations
Conditions: Endometrial Cancer
Register for Updates
A Study to Learn About Study Medicine ALTA2618 in Adults with AKT1 E17K-Mutant Solid Tumors
NCT06533059
Recruiting
The purpose of this study is to characterize the safety and tolerability of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2025
Locations: Research Site, Denver, Colorado +18 locations
Conditions: Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer, Advanced Solid Tumor
Register for Updates
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With Diet in Patients With Advanced/Recurrent Endometrial Cancer
NCT06463028
Recruiting
This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/13/2025
Locations: UC San Diego Moores Cancer Center, La Jolla, California +9 locations
Conditions: Endometrial Cancer
Register for Updates
Social Interventions for Support During Treatment for Endometrial Cancer and Recurrence
NCT04930159
Recruiting
The SISTER study is a randomized trial, looking at various modalities of social support for Black patients undergoing treatment for endometrial cancer. There are three study arms: group support, 1:1 peer support, and enhanced usual care. The primary outcome is treatment completion, and the secondary outcome is social isolation.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: University of Alabama, Birmingham, Alabama +10 locations
Conditions: Endometrial Cancer
Register for Updates
Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer
NCT05761951
Recruiting
To learn if the combination of DKN-01 and pembrolizumab can help to control advanced or recurrent endometrial cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Endometrial Cancer
Register for Updates
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
NCT05787587
Recruiting
The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: The Angeles Clinic, Los Angeles, California +24 locations
Conditions: Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, Colorectal Cancer, Head and Neck Cancers, Nsclc
Register for Updates